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THE CROSS-TALK BETWEEN
PROBIOTIC BACTERIA AND HUMAN
HOST
The human health is deemed to be main-
tained by cross-talk among the body,
probiotic and even pathogenic bacteria
within the intestine, even though the
precise molecular mechanisms governing
such intercommunication remain to be
fully understood (Corthésy et al., 2007).
The human intestinal tract encompasses
one of the most diverse microbial settings
ever discovered. In the human intestinal
lumen, the number of bacteria is approx-
imately 10 times higher more than the
number of intestinal cells. These microor-
ganisms adapted to their human host are
the natural beneficial symbionts of human
host and hence are regarded as the sec-
ond human genome (Saei and Barzegari,
2012).
It should be highlighted that the
human genome is highly stable during
lifetime. However, dependent on the life
style and/or types of nutrition, human
metagenome could be subjected to some
minor and major alterations with possi-
ble implications in modern diseases such
as asthma, allergies, cancers, and obesity
(Eslami et al., 2012). Thus, any disrup-
tion in the inherent nature of the GIT
milieu can inadvertently have unfavorable
and irreparable even tragic consequences
(Saei and Barzegari, 2012).
Today, bacteria known as probiotics are
used to maintain the microbial balance
of the GIT ecosystem—a notion which
was first suggested by Nobel laureate
Metchnikoff. Though in vitro tests have
widely been used for studying the probi-
otics, correlation of in vitro and in vivo
findings appears to be somewhat prob-
lematic. Although these studies provide
valuable information on the human
microbiome, the adaptive co-evolution
of natural microbiome and its function-
alities in human health and diseases are
yet to be fully studied. It seems that
the “Human Microbiome Project” will
help scientists answer these important
questions (Turnbaugh et al., 2007), nev-
ertheless the functional emergence of
microbiome appears as complex systems
with co-op networks in co-adaptation
with bio-components of GIT milieu.
Despite all these issues, some health
benefits have been observed for several
probiotics, whose deciphering mech-
anism(s) of action can be of utmost
significance. Perhaps, one of the major
modes of action of the probiotics is
through modulation of the host immune
system, as they are hypothesized to
invigorate the intestinal immune bar-
riers (Forsythe and Bienenstock, 2010).
The immune-enhancing effects obtained
from probiotics may be attributed
to (a) enhancement of secretion of
immunoglobulin A (Parvez et al., 2006),
(b) stimulation of pro-inflammatory path-
way, (c) regulation of interleukins (ILs),
and (d) activation of cytokine pathways
(Parvez et al., 2006).
The human intestine carries trillions of
bacteria including 400 different bacterial
species. Given that the microbial balance
is one of the key factors in human health,
maintaining the delicate balance of the
intestinal microflora is vitally important.
Correspondingly, any imbalance among
intestinal natural microflora and virulent
bacteria may inevitably result in emer-
gence of illness(s) (Barzegari et al., 2014).
PROBIOTIC THERAPY AND
CONTROVERSIAL RESULTS
People have used probiotics for many
years in the form of fermented dairy
products such as yogurt, kefir and milk.
Accordingly, after the first introduction
of health benefits of probiotics in the
early 12th century by Nobel Laureate
Metchnikoff, many bacterial strains have
clinically been tested as potential probi-
otics. Until now, reasonable evidences of
human studies and meta-analyses have
indicated the benefits of probiotics in a
variety of conditions, including short-
ening the rotavirus diarrhea (Marteau
et al., 2001), therapy of irritable bowel syn-
drome (Lee and Bak, 2011), reducing the
recurrence of bladder cancer (Feyisetan
et al., 2012), reducing the infection of
Clostridium difficile (Hell et al., 2013), low-
ering the plasma cholesterol (Hell et al.,
2013), preventing the necrotizing entero-
colitis in preterm neonates (Deshpande
et al., 2010), and preventing and treating
the pouchitis and atopic dermatitis in chil-
dren (Rautava et al., 2012). However, most
of these effects appear to be strain- and/or
population-specific (Barzegari and Saei,
2012). Why do not all studies confirm the
benefits of probiotic therapy in particular
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conditions? This is an intrigue question
that needs to be addressed. It seems the
controversial results might be related to
the dosages of probiotics and concen-
tration of bacteria used in the probiotic
supplements and diets (e.g., industrial fer-
mented milks with narrow biodiversity of
microbe starter culture) and encapsulated
forms of human non-coevolved and/or
non-native probiotics (Barzegari and Saei,
2012).
ENCAPSULATED PROBIOTICS DISTURB
HUMAN CORE MICROBIOME
The human intestine is an anaerobic biore-
actor which contains a large bacterial set-
ting composed of hundreds of species
and thousands of subspecies (Xu et al.,
2007). The number of bacterial cells in
human body is profoundly greater than
the number of human cells. Where have
these bacteria come from? Upon delivery,
when the immune system and gastroin-
testinal system have not evolved yet, the
newborn baby exposes to a wide volume
of environmental and maternal microbes
(Dominguez-Bello et al., 2010). These
microbes are also claimed for evolution
of immune as well as gastrointestinal sys-
tems (Arboleya et al., 2012), but which
microbes (indigenous symbiotic bacteria
or non-indigenous ones) are fortunate
enough to colonize the intestine? Since the
harsh conditions of gastrointestinal sys-
tem is not developed in infants and the
immune system is not evolved yet, all types
of bacteria have the same chance to enter
the infants’ gastrointestinal system. Upon
delivery especially vaginal delivery, infants
are exposed to vaginal microbes and grad-
ually they will expose to further number
of microbes through breast-feeding and
the selection of symbiotic bacteria will be
made as well (Harmsen et al., 2000). It
has been demonstrated that infants born
by Cesarean section (CS) represent dif-
ferences in their microbiota in compar-
ison with vaginally born infants (needs
reference) and correspondingly CS deliv-
ery infants expose different diseases par-
ticularly allergies (Dominguez-Bello et al.,
2010). With the evolution of immune sys-
tem and its interaction with colonized flo-
rae and the harsh condition present in
gastrointestinal system, only a particular
number of bacteria will get the certifi-
cate to colonize the intestine. Indeed the
immune system and gastrointestinal sys-
tem are coevolved with normal microflora
(Arboleya et al., 2012) and the interaction
among those guarantees the health of
human (Barzegari et al., 2014). Any inter-
ference in this homeostasis through the
encapsulation of non-indigenous bacteria
and their exposure disturbs the dominant
balance and exposes the person to diseases.
These bacteria are now considered as
the human second genome, and have been
shown to contribute to the human health
by (a) the modulation of immune sys-
tem, (b) the exclusion of the pathogens,
and (c) the association in the digestion
process. It should be highlighted that real
probiotic bacteria are those that can well
tolerate and survive the GIT transit, colo-
nize, and eventually become metabolically
active members of the human intestine.
To the best of our knowledge, ignor-
ing the high colonization potential of
the bacterial probiotics and administer-
ing them in high concentration, despite
possessing some favorable probiotic char-
acteristics but lacking the survival traits
and persistence capabilities, may disturb
the evolutionarily-developed intestinal
balance and in time give rise to some seri-
ous inadvertent imperceptible side effects.
Intestinal microflora should be considered
as complex systems. Hence, even triv-
ial alterations in microflora of intestine
accumulated in a long-term process may
elicit drastic changes within the composi-
tion and setting of intestine, which can in
return impact the intestinal microbiome
biofunctions and metabolomes as well as
human normal physiology in a holistic
manner.
People pay a lot for probiotic supple-
ments, but benefit little. Moreover, the
safety of probiotics has sometimes been
argued to be in part dependent upon
the intestinal microbiota and the status
of the host immune system (Gronbach
et al., 2010). Some probiotics have been
shown to transit the GIT intact with no
persistence. Further, the spurious probi-
otics appear to be undetectable after the
termination of the consumption course
of the probiotics. Some studies convinc-
ingly demonstrated that most ingested
strains fail to become persistent mem-
bers of the intestinal microbiota, while
solely some stains show short-term per-
sistent viability after the course of the
administration (Klingberg and Budde,
2006). For instance, L. reuteriwas reported
to be detectable solely in four and two (out
of nine volunteers examined) respectively
1 and 2 weeks after the termination of
the probiotic administration (Smith et al.,
2011). All experts in the field agree that
persistent viability of the administered
probiotics within the GIT is a determin-
ing indicator for the efficacy of probiotics,
however the health promoting outcomes
may be intriguingly challenging. All these
happen because the isolated strains, used
as probiotics, are not either from the
human origin, indigenous or even not
carefully selected according to the cri-
teria set forth by FAO/WHO guidelines
(Figure 1).
As stated before, indigenous probiotic
bacteria can tolerate the harsh conditions
of the GIT (Iyer et al., 2005), while non-
indigenous bacteria are relatively intoler-
ant to such harsh conditions. Even if the
encapsulation has shown to enhance the
survival rate of probiotics within the GIT
milieu, prior to their administration, some
important unclear issues need to be fully
addressed. Are not supposed the probiotic
bacteria to be resistant to the GIT condi-
tions as disclosed in FAO/WHO guidelines
and analyzed by in vitro acid and bile tests?
If so, why should one attempt to encap-
sulate the probiotics in order to enhance
their viable delivery into the intestine?
To protect the viability of the probi-
otic bacteria during transition into the
intestine, several methods of encapsula-
tion (e.g., spray drying, extrusion, emul-
sion) have been developed using different
types of biopolymers such as alginate,
gelatin, chitosan, and cellulose derivatives
(Huq et al., 2013; Shi et al., 2013; Tee
et al., 2013). Probiotic encapsulation is
not always under question because it can
enhance the survival rate of probiotics,
increase their tolerance during food pro-
duction processes and lyophilization, and
preserve their viability in long-term stor-
age (Huq et al., 2013).
However, the encapsulation process
may elicit undesired impacts by introduc-
ing a high number of inappropriately-
selected bacteria into the intestine and
hence inducing inevitable interference
with the natural intestinal ecosystem.
Furthermore, the concept of viable pro-
biotics can sometimes be questionable,
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FIGURE 1 | WHO Guideline for isolation and application of probiotics.
since dead probiotic cells have also been
shown to induce some biological responses
mainly by the immune system of the host
(Adams, 2010). The symbiosis of intesti-
nal microbiota with the human intes-
tine has occurred over many millennia of
adaptive coevolution, leading to a com-
plex biological and reciprocal relationship
between bacterial and Homo sapiens cells
(Ley et al., 2008). Thus we cannot expect
an outlander, a bacterium which does not
belong to this setting, or one that has not
been able to live within such symbiosis
with human intestine through the many
years of coevolution, to serve as a probi-
otic. Therefore, unknown interactions of
these pseudo-probiotics can lead to pos-
sible alterations in human metagenome.
If these bacteria were favorable to their
human host, they would not be filtered by
the defensive mechanisms of GIT. Hence,
encapsulation of probiotics for enhancing
their survival rate during GIT transition
looms to be a matter of rigorous scientific
debate. In fact, “to think that we can inter-
vene effectively in human–microbe rela-
tionships without considering microbial
ecology and evolution” is not a scientif-
ically sound approach (Dethlefsen et al.,
2007).
Since the probiotic-intestinal
machineries are very sensitive at molec-
ular levels and also the immune system
can be modulated by even small amounts
of an antigen, the nature and the num-
ber of bacteria in probiotic supplements
should necessarily be revisited based upon
the natural setting of the intestine. To
benefit the consumer, the minimum rec-
ommended number of viable bacteria in
food products has been suggested to be
107 CFU per mL at the time of consump-
tion, while lower or higher number of
bacteria may be demanded for a specific
biological function. This issue again can be
dependent on (a) the strain used, (b) the
intestinal microbial balance, and (c) the
pathophysiologic condition that is going
to be treated. The large intestinal micro-
biome species (Xu et al., 2007) is indeed
an interwoven complex bionetwork com-
posed of trillions of interactions. Then,
imposing high numbers of only one spe-
cific probiotic may upset the equilibrium
of intestinal microbiome or change it in
favor of certain strain(s). It seems that the
recommended number of probiotic bacte-
ria (107 CFU per mL), which should exist
in probiotic preparations, comes without
a scientifically sound basis and seems to
be somewhat over-generalized approach
that may not visit all facts required for all
probiotic strains and for all the purposes
of the administration.
DISCUSSION
The harsh conditions of GIT (i.e., the
presence of acid, pepsin, bile salts and
pancreatic secretions) hinder majority of
the ingested microorganisms to enter the
intestine and also protect human body
against the undesired interfering bacte-
ria (Schwabe and Jobin, 2013). Only
a small portion of these microorgan-
isms co-evolve with human intestine in
a way that they can tolerate such hos-
tile environment and build the naturally
adoptive intestinal microbiome. Thus,
the balance of the intestinal ecosystem
is determined/maintained by a robust
appointive/selective process imposed by
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the GIT environment, human genet-
ics and lifestyle (Schwabe and Jobin,
2013). The importance of such selective
microbiome is extremely complex and
immense, which is regarded as human sec-
ond genome/metagenome. Having consid-
ered these facts, any irrational manipu-
lation of the intestinal microbiome can
have undesired and sometimes irreversible
harsh consequences. In addition, the
intestinal dysbioses is associated with
a variety of modern diseases such as
malignancies (in particular colon can-
cer), diabetes, ulcerative colitis, inflamma-
tory bowel disease, and multisystem organ
failure (Cho and Blaser, 2012; Schwabe
and Jobin, 2013). Further, introduction of
non-indigenous probiotics into the human
intestine can lead to some alterations in
the microbiome and metagenome, result-
ing in emergence of metabolic syndrome,
autoimmune diseases, and probably epi-
genetic disorders in a short- or long-
term period. Moreover, even accumu-
lation of large numbers of indigenous
probiotics can disrupt the complex and
dynamic ecosystem of the intestine. In
fact, little is known about the intesti-
nal microbiome and its cross-talk with
the human intestine, hence great care
should be taken into account when select-
ing probiotic bacteria for an individual
with certain health condition—perhaps
we should consider probiotic supplements
as personalized medicines.
To conclude, we envision that multi-
probiotic therapy and holistic personalized
microbiome supplements may be scientif-
ically justified and valued in individual-
ized probiotic designs and even targeted
therapy of life-threatening diseases such as
cancers in the future. Subsequently, con-
sumer health settings and advancements
in science, all should specially be attended
in the probiotic design modalities and
strategies, rather as personalized medica-
ments. Although the guidelines imposes
extra costs and labor, and time to charac-
terize good probiotics, the isolation of real
indigenous, beneficial bacteria may also
provide some advantages. Respecting the
scientific disciplines has the potential to
increase the public awareness about the
health benefits of real probiotics. How nice
it would be if we could imagine a future in
which probiotics are incorporated in our
drug pharmacopeias with their associated
health benefits! In such a future, peo-
ple could truly believe in probiotics, and
probiotics could even be considered and
consumed as personalized medication.
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